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Febrile neutropenia requires adequate antibiotic treat-
ment. A subgroup of patients are only at low risk for
complications and could be treated at home/as outpa-
tients (OHPAT) after a short initial admission for work
up. This position paper by a Belgian panel of experts
presents criteria defining low-risk in febrile neutrope-
nia, gives an overview of the existing experience and
examines the present obstacles to a more widespread
use of OHPAT in this country.
INTRODUCTION
A panel of Belgian experts, has examined the feasi-
bility of OHPAT in febrile neutropenia in this country.
An introductory document, reviewing the history of and
summarizing the available clinical experience with am-
bulatory antibiotic administration in febrile neutrope-
nia and other indications was prepared by an independ-
ent copy-writer. Panel participants reviewed this text and
three meetings were subsequently held (April 19th 1999,
October 18th 1999 and April 3rd 2000), during which the
various aspects of the subject were extensively discussed.
Audio tapes served as a basis for the minutes and addi-
tional literature references were gathered. Thereafter, a
draft manuscript was prepared, and reviewed several
times by all participants independently, under the guid-
ance of one of the authors (Y.B.). The project was sup-
ported by Aventis Pharma. The present document sum-
marizes the pro’s and con’s of this approach, and exam-
ines the various problems in the present situation, from
an organizational, legal and financial point of view.
Over 30 years ago, Bodey (1) recognized that most
neutropenic patients experience febrile episodes during
anticancer chemotherapy, especially for those having
prolonged and/or pronounced neutropenia (WBC count
< 500/mm3). Clinical signs alone, however, do not al-
ways enable us to distinguish between life-threatening
bacteremic episodes and other less severe infections, or
even non-infectious conditions (2). Since mortality is
increased when antibiotic treatment is delayed (3) - death
rate reaching 80% in Gram-negative sepsis, for instance
– it has become common practice to start broad spec-
trum antibiotics empirically at the onset of fever, mostly
as an association of several parenteral compounds but
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also as broad-spectrum monotherapy.
In many western countries, budgetary restrictions
impose severe cuts on health expenditures, and one is
looking for safe but less expensive approaches to the
treatment of many medical problems. Hospital admis-
sion as such represents a major burden to the financial
envelope. Since twenty years, parenteral antibiotics have
occasionally been administered on an outpatient basis.
The very first reference to this method has been pub-
lished in 1974 (4) in cystic fibrosis pediatric patients,
whereas the first mention in adults dates back to 1978
(5). Nowadays, OHPAT represents 250,000 patients per
year in the US (6).
OHPAT has been widely used to treat bacterial en-
docarditis (7). These patients mostly need a lengthy hos-
pital stay and clearly benefit from this approach. Their
often precarious clinical condition somehow limits the
feasibility of this method and most series report the per-
centage of OHPAT in this disease to be around 5% (8).
As far as glycopeptides are concerned, some experience
has been gained with a thrice-a-week or even twice-a-
week administration of teicoplanin on an outpatient ba-
sis (9). OHPAT offers many advantages in the case of
bacterial osteomyelitis or arthritis. Most patients do not
require hospitalization because of their general condi-
tion, and the prolonged stay is the result of the need for
parenteral antibiotics only. A recently published docu-
ment (10) gives an overview of this topic. Besides these
two main indications, OHPAT has been used in the man-
agement of community-acquired lower respiratory in-
fections and in cystic fibrosis (11), in the therapy of skin
and soft tissue infections (12), in central nervous sys-
tem infections (13) and in the HIV arena (14).
Oral antibiotherapy has been compared to intrave-
nous antibiotherapy in neutropenic patients receiving
anticancer chemotherapy (15,16), but some experience
has been gained with OHPAT as well in febrile neutro-
penia. In 1994, a pilot study on 30 patients concluded
that early discharge of low-risk patients on OHPAT is
feasible, well received and cost-saving (17). In 1996 and
again in 1999 (18,19), Rolston stated that OHPAT of
low-risk patients resulted in a reduction of cost of
therapy, better resource utilization and enhanced qual-
ity of life. In the pediatric setting, terminally ill patients
with malignancies have been treated with OHPAT dur-
ing febrile episodes (20).
Even though some clinical studies indicate suc-
cessful outcome with OHPAT, they are either retrospec-
tive or of limited size when prospective. Although some
studies use a reliable scoring system to assess the real
risk (17), this approach is unfortunately not widespread.
Yet, it might otherwise allow treatment of a larger pro-
portion of patients, when a subgroup with predictable
low-risk becomes clearly defined.
ADVANTAGES AND DRAW-BACKS OF
OHPAT
For the present time, most neutropenic patients with
a febrile episode are treated in the hospital setting. This
provides opportunities for close monitoring in a safe
environment, easy access to intravenous treatment, and
fast intervention in case of unforeseen complications.
On the other hand, cost of treatment is high and the qual-
ity of life is largely impaired. OHPAT offers many ad-
vantages, as reported in the prospective studies by Malik.
(21,22).
a) Advantages of OHPAT
Financial savings
Nowadays, cost-benefit analyses are a difficult
endeavor as they should take into account direct cost
savings (hospital stay, physician visits, drugs and sup-
plies, childcare, housekeeping, transportation …) as well
as indirect benefits (lost wages, both for patient and fam-
ily members) (23). In a cohort of 30 patients, attending
the day ward of a large London hospital because of
chemotherapy courses through central lines, savings up
to 3.000 £ per individual have been found in patients
switched to OHPAT in combination with an oral
fluoroquinolone, as compared to intravenous hospital
treatment with a ß-lactam and aminoglycoside combi-
nation (24). In another study (25), 5.2% of patients or
11% of those receiving antibiotics in a 54 beds unit could
benefit from OHPAT. The total cost of intravenous drugs
in the classical in-hospital treatment was cheaper by 44 £
overall, as compared to the ambulatory treatment. But,
and this more than compensates for the cost of drugs,
532 hospital days were saved during the study period.
Williams (26) showed clear evidence for the cost effec-
tiveness of OHPAT programs.
Decreased prevalence of nosocomial infections
Keeping patients out of hospital should reduce the
prevalence of hospital-acquired infections. Indeed, it has
been shown that nosocomial infections affect 5% of
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hospitalized patients, and increase with every day of stay
(27,28). They are a particular threat to granulocytopenic
patients. However, this theoretical advantage has not
been substantiated yet in patients with neutropenia of
short duration.
Improved quality of life (QOL)
The psychosocial benefit of staying at home is diffi-
cult to quantitate. The ability to attend school for chil-
dren and to resume work for employed adults has been
described to be as high as 96% and 90%, respectively,
in one study (29). In the pediatric setting, incentives for
keeping children or even infants out of hospital are even
stronger (parental occupations, psychological trauma-
tism, school attendance …). The Parker study (25) also
identifies facts perceived as advantages or disadvantages
for OHPAT by general practitioners and patients in the
United Kingdom (Table 1). Not all of these may apply
to the Belgian situation.
b) Adverse effects of OHPAT
In 1999, a group from Pennsylvania reviewed the
medical records of 269 patients (291 courses of treat-
ment) receiving home parenteral antimicrobial therapy
(30), scrutinizing the adverse effects. HIV-patients were
excluded from the analysis, and the reason for OHPAT
was osteomyelitis in 59% of cases. Taking the different
characteristics of this population into account, one notes
that the most common side effect of OHPAT was a de-
pression of the WBC count (both leucopenia and neu-
tropenia) and of the platelet count, mostly linked to long-
term use of ß-lactams. Further, nephrotoxicity (8%),
diarrhea (7%) and rash (4%) were noted. Line compli-
cations occurred in 11% of central catheters and 9% of
the peripheral lines. Overall, admission was needed in
8% of the patients. Obviously the risks for the patients
also depended on the type of complications for which
antibiotics were given and not only on line- or drug-
related events. The authors concluded that complications
are roughly the same as those expected with inpatients.
We are not aware of any such study specifically address-
ing neutropenic patients.
PROGNOSTIC FACTORS OF INFECTION
OUTCOME
For the above-mentioned reasons, one would like to
be able to discharge patients early, after a short admis-
sion for work-up and for initiating antimicrobial treat-
ment. One should clearly delineate a “low-risk” group
of patients, with criteria easy to apply in daily medical
practice.
Table 1: Advantages and disadvantages of OHPAT, as evaluated in the United Kingdom (adapted from (25))
ADVANTAGES DISADVANTAGES
TO GENERAL • saves hospital admissions • increased work-load
PRACTITIONER • maintains GP responsibility • concern about safety at home
• makes home management possible • costs to GP budget
• reduces hospital billing to GP • distance from hospital
• speeds up access to hospital • some loss of responsibility
 TO PATIENT • own environment • distance from hospital
• no travel for relatives • lack of nursing care
• quicker improvement • worries of relatives
• better contact with GP • ill patients should be in hospital
• less stress • lack of compliance
• happier relatives • anxiety
• possibility of worse outcome
• infection risk of the IV site
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a) Features of the patient in general
Over the last few years, various sets of guidelines
have been proposed on both sides of the Atlantic, to try
to determine in advance which patients could be con-
sidered low-risk for complications (17, 31-37). The fol-
lowing criteria seem very important:
- depth of neutropenia: a nadir of neutrophils below 500/
µL, and even more so below 100/mm3, is associated
with a much increased risk for severe pneumonia and
sepsis
- duration of neutropenia: expected duration of 7 to 10
days is often used as cut-off point.
- low monocyte count: monocyte count < 100/µL
- hospitalization for other underlying medical problems
- uncontrolled cancer
- type of cancer: solid tumors have a more favorable
course than acute leukemias
- type of treatment: maintenance therapy is more
favorable than induction chemotherapy. Stem cell or
bone marrow transplantation also carries a higher risk.
However, Herrmann (38) recently showed that a group
of 51 Hodgkin’s and non-Hodgkin’s lymphoma pa-
tients (including high dose chemotherapy and autolo-
gous peripheral stem cell transplantation) could ef-
fectively be managed at home, and compared well with
a group of 88 patients receiving similar treatment in a
hospital setting.
- serious comorbidity (heart failure, chronic obstructive
pulmonary disease, diabetes, recent surgery) worsens
the prognosis
- clinical signs: following signs carry a poor prognosis:
hypotension, neurologic changes and alteration of con-
sciousness, dyspnea, abdominal pain, dehydration,
bleeding, heart failure or arrhythmias, hepatic or re-
nal failure, extensive cellulitis
b) Characteristics of the infectious process
After wide clinical use of the first ß-lactams, Gram-
negative organisms became the first cause of sepsis in
neutropenics during the sixties and the seventies. After
the introduction of broad spectrum compounds and wide-
spread quinolone prophylaxis, at the turn of the eighties,
Gram-positive cocci became more and more important.
At the present time, Gram-positive micro-organisms
cause some 60% of all bacteremias in the neutropenic
(39). This might be due to the widespread use of tunneled
central venous catheters, fluoroquinolone prophylaxis
and to the mucositis accompanying intensive chemo-
therapy. This, together with the rise of some fungi (Can-
dida spp. and Aspergillus fumigatus), has had an impact
on the empiric choices.
A high number of febrile episodes remains without
known cause, even after extensive work-up: 66% of fe-
vers remain unexplained according to the American
National Cancer Institute and the EORTC (2). Fever of
unknown origin conveys a worse prognosis in non-neu-
tropenic patients, but this does not seem to be true in
febrile neutropenia. (31). However, unspecified infec-
tions will often require many changes in antibiotic treat-
ment, in itself a risk factor. Amongst specific infections,
uncomplicated urinary tract infections and catheter exit
infections have a better prognosis than extensive pneu-
monia or than infection of the subcutaneous catheter
tunnel. The virulence of the micro-organism determines
the outcome. For instance, catheter-related bacteremia
caused by coagulase-negative staphylococci has a bet-
ter prognosis than Gram-negative sepsis.
DEFINITION OF LOW-RISK
NEUTROPENIA
In Talcott’s paper (32), the risk groups were defined
as follows:
- group 1: inpatients at the time of fever appearance
- group 2: outpatients with concurrent comorbidity
- group 3: same as 2 but uncontrolled cancer
- group 4: neutropenic outpatients with fever but with-
out risk factors. The latter was considered “low-risk”.
Taking into account the experience detailed above,
particularly that of the EORTC and of Talcott, the Mul-
tinational Association for Supportive Care in Cancer
developed an internationally validated scoring system
(36). We summarize here the factors contributing to the
risk index in that document:
- absence of symptoms or mild symptoms (5 points) or
moderate symptoms (3 points)
- absence of hypotension (5 points)
- absence of chronic pulmonary obstructive disease (4
points)
- solid tumor or absence of previous fungal infection in
hematologic patients (4 points)
- absence of dehydration (3 points)
- outpatient status (3 points)
- age younger than 60 years (2 points)
A risk-index score ≥ 21 identified low-risk patients
with a specificity of 91%.
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On the other hand, many factors may also prevent
discharge:
- allergy to the drugs contemplated for OHPAT
- microbial resistance to contemplated antibiotics
- need for hospitalization for concomitant medical con-
ditions: renal failure, hepatic failure, shock, respira-
tory failure, bleeding, cardiac failure or arrhythmias,
extensive mucositis or cellulitis …
- need for other IV lines (rehydration, other drugs …)
- inability to ensure proper hydration and/or to take oral
medications
- inadequate reliability and psychosocial environment
- central nervous system infections
- allogeneic stem cell transplantation
- induction chemotherapy
PRACTICAL CONSIDERATIONS
a) Short admission to hospital for work-up
Most authors will agree that a short admission
(48 hours) is necessary for work-up in neutropenic pa-
tients with unexplained fever. It will also enable the phy-
sicians to obtain the results of at least some laboratory
tests (e.g. blood cultures, expectorations, urine culture)
and to initiate antibiotic treatment adequately. During that
period, it will be critical to determine the risk category of
the patient and to document the origin of infection. Every
effort will be made to localize the origin of the fever, all
necessary samples will be sent to the microbiology labo-
ratory and antibiotic treatment will be started, largely on
an empiric basis. A review from the Infectious Diseases
Society of America (35) describes the available options:
[1] combination therapy with an aminoglycoside plus
either an antipseudomonal penicillin, a 3rd or 4th genera-
tion cephalosporin, or a carbapenem; [2] if the use of
vancomycin is justified, choose a combination of vanco-
mycin and either an antipseudomonal penicillin, cefepime,
ceftazidime or a carbapenem, with or without an
aminoglycoside. The attitude will be reassessed if fever
persists after 36-72 hours. After that initial work-up phase,
low risk patients will possibly be discharged. Some low
risk patients may be eligible for oral antibiotics, but this
is beyond the scope of this paper.
b) Antibiotics and supportive care
Broad-spectrum antibiotics suitable for once-a-day
intravenous administration belong to three categories:
- aminoglycosides (all the molecules available in Bel-
gium)
- cephalosporins (ceftriaxone in particular)
- glycopeptides (teicoplanin in particular).
As an alternative, molecules with a shorter half-life
can be chosen, making use of slow infusion devices.
Detailed reviews on the pharmacokinetics of antimicro-
bial drugs and on infusion devices available for outpa-
tient use have been published (40,41). Most of the times,
ceftriaxone will be the treatment of choice. For docu-
mented or probable infections with Gram positive cocci,
teicoplanin will be the treatment of choice. Duration of
treatment will be guided by clinical judgment and re-
covery from neutropenia, and will usually range from 5
to 8 days.
According to ASCO recommendations (42), there is
strong evidence that colony-stimulating factors (CSF)
cannot be recommended as routine adjunct therapy for
the treatment of uncomplicated fever and neutropenia.
Uncomplicated fever and neutropenia are defined as
follows : fever < 10 days in duration ; no evidence of
pneumonia, cellulitis, abscess, sinusitis, hypotension,
multiorgan dysfunction or invasive fungal infections ;
and no uncontrolled malignancies. All trials have con-
sistently shown a decrease in the duration of neutrope-
nia < 500/µl, but clinical benefit has not consistently
accompanied the decreased duration of neutropenia.
c) Potential alternatives for the IV administration
In any case, the patients and their family will be given
a list of useful telephone numbers, and the address of
the emergency ward of the hospital in charge, in case of
unforeseen complications. These facilities should be ac-
cessible 24 hours a day. A new admission will be con-
templated in case of reappearance of fever. However,
this eventuality seems rather infrequent. Two alterna-
tives are possible for antibiotic administration. General
organizational aspects of these alternatives in neutro-
penic and non-neutropenic patients have been reviewed
(43).
On a day clinic basis
Where no financial intervention from Social Secu-
rity is available, patients attend the day clinic, on a daily
or thrice-a-week basis (9). The nursing team adminis-
ters the parenteral injection and the physician takes ad-
vantage of the patient’s presence to check the vital signs
and the clinical evolution. In our country, some teams
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occasionally treat individual adult patients with OHPAT
(personal communication, Dr. D. Vogelaers, Infectious
Disease specialist, University Hospital Ghent and Dr.
D. Selleslag, oncologist, AZ St Jan, Brugge). To illus-
trate this point, we mention the following case report
(courtesy of Dr. Selleslag).
A 60-year-old AML patient in remission was on out-
patient maintenance therapy with monthly cycles of low
dose cytarabine. He developed fever of 39°C when the
neutrophil count was 300/µl. There was no sign of in-
fection on clinical examination and blood pressure was
normal. Chest X-ray was normal. He was admitted for
work-up and was started on empiric antibiotic treatment
(ceftazidim and amikacin). After 48 hours, all blood
cultures became positive for Staphylococcus epider-
midis, susceptible to glycopeptides only. The bacteremia
presumably originated from a double lumen Hickman
line, although no sign of exit site or tunnel infection was
present. The Hickman line was kept in place because of
peripheral venous access problems. Treatment was
switched to teicoplanin 800 mg IV/day, making use of
another lumen of the catheter every day. The patient
became afebrile 72 hours after admission. As he ful-
filled the criteria for low-risk neutropenia, he completed
treatment for another 7 days at the day clinics. More
than 2 months after the last chemotherapy, the Hickman
line is still in place, without recurrence of bacteremia.
This case report illustrates the feasibility of outpatient
treatment with once-a-day antibiotics for coagulase nega-
tive Staphylococcus catheter-related bacteremia in pa-
tients with low risk neutropenia.
As home treatment
Practice guidelines for community-based parenteral
antibiotherapy have been published (44). In the Nether-
lands, some teams have accumulated experience with
home parenteral antibiotics (45-47). The hospital phar-
macy delivers all the needed material (drugs, IV lines,
syringes, dressings …), a financial agreement is reached
with Social Security or, alternatively, sponsoring is or-
ganized with private funding. In some instances, nurses
have been especially trained to educate the patients and
perform the first administration at home. In order to be
able to achieve home parenteral antibiotics, some prac-
tical problems need to be tackled:
- budgetary issues: parenteral antibiotics often cannot
claim reimbursement on an out-of-hospital basis,
medical advice from the oncologist in charge is often
not paid for, community pharmacies are not always
able to charge for the necessities.
- organizational issues: the relay between hospital and
home care is less than perfect, as far as exchange of
medical information is concerned (link between gen-
eral practitioner and hospital oncologist), but also con-
cerning nursing needs (private home nursing systems
or free-lance nursing personnel). Moreover, some
drugs or technical devices may not be available for
out-of-hospital use.
- qualification issues: the private nurses are not always
acquainted with the type of care needed and the gen-
eral practitioners may be reluctant to take full respon-
sibility for cancer patients, especially acute leukemias.
At this point, one must emphasize the importance of
trained nurses, able to interact with the hospital and
the community health care providers (city nurses, gen-
eral practitioners, family …).
EXPERIENCE IN GHENT:
THE “KOESTER PROJECT”
The Koester project (for “Kinder Oncologische Eenheid
voor Specifieke Thuiszorg En Rehabilitatie”) started in
1990 at the Akademisch Ziekenhuis Ghent under the guid-
ance of Prof. Y Benoit (Pediatric onco-hematologic de-
partment) and Dr. G Laureys (Department of Pediatrics).
After initial work-up during a short hospital stay for pro-
viding precise diagnosis, taking all necessary samples and
initiating treatment, most febrile neutropenic patients come
into consideration for further home treatment. Of these, a
selected (see table 2 for criteria) subgroup is discharged
on parenteral antibiotics – either a once-a-day third gen-
eration cephalosporin and an aminoglycoside in case of
susceptible Gram-negative infection, or a once-a-day
glycopeptide for Gram-positive infections, mostly due to
methicillin-resistant staphylococci.
The team consists of permanent collaborators
available in the hospital and, for home interventions, of
pediatricians, oncologists, psychotherapists and 3 spe-
cially trained nurses who interact with the home care
(physician, community nurses, patient’s close relatives).
They are reachable 24 hours a day and make very pre-
cise instructions available, together with a list of useful
telephone numbers (pediatrician in charge, emergency
ward of the teaching hospital, general practitioners on
call …). The medicines, as well as all the necessary ac-
cessories, such as perfusion kits, needles, dressings are
dispatched through the hospital pharmacy. Financial
support is provided in part by the association
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“Kinderkankerfonds, vzw”. A prospective study is still
ongoing concerning various aspects of this project.
CONCLUSION
Febrile neutropenia has undergone profound changes
over the last decade. A subgroup of low-risk patients
can be delineated that is amenable to out-of-hospital
treatment. OHPAT is widely used in other severe infec-
tious conditions (such as endocarditis, osteomyelitis,
HIV infection …) and is already common practice in
the pediatric setting of febrile neutropenia in our coun-
try. A few limiting factors, mostly of financial and or-
ganizing nature, prevent the spread of home parenteral
antibiotherapy to adult cancer patients at large. How-
ever, OHPAT can widely be provided in the outpatient
clinics.
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